• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Neurosci. Author manuscript; available in PMC Oct 21, 2010.
Published in final edited form as:
PMCID: PMC2866018
NIHMSID: NIHMS197620

Co-trafficking of SV2 and synaptotagmin at the synapse

Abstract

Synaptic vesicles are specialized cycling endosomes that contain a unique constellation of membrane proteins. Proteins are sorted to vesicles by short amino acid sequences that serve as binding sites for clathrin adaptor proteins. Here we show that a tyrosine-based endocytosis motif in the vesicle protein SV2 is required for trafficking to synaptic vesicles of both SV2 and the calcium sensor protein synaptotagmin. Aberrant neurotransmission in cultured hippocampal neurons lacking SV2 was rescued by expression of wild-type SV2A, but not by SV2A-Y46A, a mutant containing a disrupted endocytosis motif in SV2A's cytoplasmic amino terminus. Neurons expressing SV2A-Y46A had significantly more SV2 on the plasma membrane, indicating reduced internalization. A screen for proteins that preferentially bound wild-type SV2A identified multiple endocytosis-related proteins, and in vitro binding studies confirmed binding to the clathrin adaptors AP2, EPS15 and amphiphysin2/Bin1. Neurons lacking SV2 contained less synaptotagmin and had a higher proportion of synaptotagmin on the plasma membrane. Expression of either wild-type SV2A or SV2A-Y46A restored synaptotagmin expression levels, however, only wild-type SV2A restored a normal proportion of synaptotagmin on the plasma membrane. These findings indicate that SV2 influences the expression and trafficking of synaptotagmin via separate mechanisms. Synaptic vesicles immunoisolated from SV2A/B double knockout mice had significantly less synaptotagmin than vesicles isolated from wild type mice. Our results indicate that SV2 plays a major role in regulating the amount of synaptotagmin in synaptic vesicles and provide an explanation for the observation that synapses lacking SV2 have fewer vesicles competent for calcium-induced fusion.

Keywords: SV2, endocytosis, transporter, neurotransmission, synapse, AP2 (adapter protein 2)

Introduction

Proteins unique to regulated secretion mediate the refinement of exocytosis that occurs at neuronal synapses. Among these is the membrane protein SV2, which is specific to secretory vesicles in neurons and endocrine cells. Mammals have three SV2 genes that encode isoforms termed SV2A, SV2B, and SV2C. SV2 is an essential protein. Mice lacking the most widely expressed isoform, SV2A, develop severe seizures and die within three weeks of birth (K. M. Crowder et al., 1999; R. Janz et al., 1999).

SV2A is the binding site of levetiracetam (B. A. Lynch et al., 2004), an FDA-approved drug that is currently used in the treatment of epilepsy (reviewed in (T. De Smedt et al., 2007)), and which also shows promise for the treatment of anxiety disorders (W. Zhang et al., 2005; G. Kinrys et al., 2006; G. Kinrys et al., 2007), pain (M. J. Price, 2004; E. D. Dunteman, 2005; T. P. Enggaard et al., 2006), dyskinesias (C. L. McGavin et al., 2003; K. O. Bushara et al., 2005; P. Striano et al., 2007; S. W. Woods et al., 2008; S. A. Zivkovic et al., 2008), and post-traumatic stress disorder (G. Kinrys et al., 2006). At present SV2 is the only drug target in synaptic vesicles.

Analyses of neurotransmission in mice lacking SV2A reveal a significant decrease in evoked vesicle fusion in both excitatory (K. L. Custer et al., 2006) and inhibitory (K. M. Crowder et al., 1999; W. P. Chang and T. C. Sudhof, 2009) CNS neurons, as well as in cultured chromaffin cells (T. Xu and S. M. Bajjalieh, 2001). This effect is limited to calcium-induced neurotransmission as there is no difference in the frequency of spontaneous transmitter release (K. M. Crowder et al., 1999; K. L. Custer et al., 2006).

All SV2 isoforms bind the synaptic vesicle protein synaptotagmin (A. E. Schivell et al., 1996; D. R. Lazzell et al., 2004; A. E. Schivell et al., 2005). Loss of SV2B, the predominant isoform in retinal photoreceptors, results in decreased levels of synaptotagmin 1 in photoreceptor synapses (D. R. Lazzell et al., 2004; C. W. Morgans et al., 2009). This suggests that SV2 influences the expression, trafficking, or stability of synaptotagmin. SV2 does not appear to affect vesicle formation, however, since synaptic morphology and vesicle density are not altered in SV2 knockouts (K. M. Crowder et al., 1999; R. Janz et al., 1999; C. W. Morgans et al., 2009). Together these observations suggest that SV2 could influence neurotransmitter release by regulating the amount of synaptotagmin in secretory vesicles. Here we report that mutation of a tyrosine-based endocytosis motif in SV2A results in a non-functional protein that disrupts the endocytosis of both SV2 and synaptotagmin. Thus SV2 plays a crucial role in the trafficking of synaptotagmin to synaptic vesicles and regulates the effectiveness of calcium in inducing vesicle fusion by regulating the vesicle content of a major calcium sensor protein.

Materials and Methods

Plasmids

Site-directed mutagenesis of rat SV2A cDNA in pCDNA3.1 was carried out using a QuikChange Site-Directed Mutagenesis kit (Stratagene). Tyrosines 46 and 443 were replaced with alanine. The primers used included: Y46Af 5′- CGA AGG TCC GCC TCC CGC TTT GAG GAG GAG GAG-3′, Y46Ar 5′-AAA GCG GGA GGC GGA CCT TCG GGA ATA TTC ATC CTG-3′, Y443Af 5′-AGT CCA GAG GCC CGG CGC ATC ACT CTG ATG ATG-3′, and Y443Ar 5′-GAT GCG CCG GGC CTC TGG ACT GAA GCA GGA GAG-3′ (f and r denote forward and reverse primers. Underlined letters indicate mismatches). To make the Y46A/Y443A double mutant, a Nhe I/Sac II fragment in SV2A-Y443A pCDNA3.1 was replaced with the corresponding fragment from a SV2A-Y46A pCDNA3.1 construct. All constructs were sequenced to ensure that no additional mutations were introduced during PCR amplification. The coding sequences of the mutant SV2As were subcloned into EGFP-pRRL vector to generate a lentiviral construct carrying the SV2A gene with EGFP fused to its C-terminus.

Primary hippocampal neuron culture and viral gene delivery

Microisland cultures of primary hippocampal neurons were prepared as described previously (K. L. Custer et al., 2006). Cultures were infected with Lenti virions as described below and used for electrophysiological recording or FM 4-64 labeling experiments at 12-16 days in vitro (DIV). Conventional hippocampal neuron cultures were prepared on 6 well plates pre-coated with poly-D-lysine. Generally, 2-3×105 cells/well were maintained in astrocyte-conditioned neuron media supplemented with 80μM of the mitosis inhibitor (5-Fluoro-2′-deoxy-uridine) (Sigma) to suppress the growth of astrocytes. Cultures were infected with Lenti virions at 2-3 DIV and used for surface biotinylation experiments at 13-15 DIV.

Lentiviral gene delivery

Virions generated from Lenti virus carrying the SV2A-EGFP cDNAs were produced in HEK293T fibroblasts. Briefly, cells were co-transfected with packing plasmids pLP1, pLP2, pLP VSV-G and the carrier vectors containing SV2A-EGFP using calcium phosphate. Sixteen hours post-transfection the medium was replaced with fresh medium. Media containing Lenti virions were harvested twice from the culture. Media were filtered through 0.22 μm pore PVDF membranes and concentrated by centrifuging at 6,700×g for a minimum of 16 hours at 4 °C. The virion pellets were resuspended in medium and stored at -80 °C.

Immunocytochemistry

Antibody labeling of hippocampal neurons expressing exogenous SV2 was performed at 12-15 DIV as previously described (K. L. Custer et al., 2006) using an anti-synaptophysin monoclonal (1:2000 dilution, Chemicon, Temecula, CA) and a polyclonal antibody directed against SV2A (S. M. Bajjalieh et al., 1994) (1:1000 dilution). Immunolabeling of neurons cultured from SV2A/B DKO mice utilized a polyclonal antibody against synaptotagmin 1 and a monoclonal antibody against synaptophysin. Antibody labeling was detected with fluorescent secondary antibodies (Goat-anti-rabbit Alexa-Fluor 488 and goat-anti-mouse Alexa-Fluor 568; or goat-anti-rabbit Alexa-Fluor 568 and goat-anti-mouse Alexa-Fluor 647, Invitrogen, Eugene, OR). Images were obtained with a confocal laser-scanning microscope (SP1 Confocal; Leica, Bannockburn, IL) with a 100× PL APO N.A. 1.40 oil immersion objective. Images of SV2-expressing neurons were processed and assembled using Adobe Photoshop (Adobe Systems, San Jose, CA). Analysis of synaptotagmin 1 immunofluorescence was performed with MetaMorph image software with anti-synaptophysin labeling used to define synaptic puncta.

FM 4-64FX labeling

Coverslips of DIV 11-15 mouse hippocampal neurons cultured as for physiological analyses were rinsed in external solution (K. L. Custer et al., 2006) containing 2 mM CaCl2 and 4 mM MgCl2 and challenged with a high-potassium solution in the presence of 10μg/ml FM4-64FX (Molecular Probes) for 60 s (in mM: 60 KCl, 64 NaCl, 30 glucose, 20 HEPES, 2 CaCl2, and 4 MgCl2, 0.01 glycine). Excess dye was removed with seven 1 min rinses in Ca2+-free external solution, two of which contained 300 μM Advasep-7 (Biotium, Hayward, CA). Immediately after rinses, neurons were fixed in 4% paraformaldehyde, rinsed with 0.1 M glycine in PBS and mounted on glass slides for confocal microscopy. Images were taken using SP1 Leica confocal microscope with equal exposure settings in the red (FM4-64) channel and analyzed with MetaMorph image software. Images were thresholded based on SV2A-EGFP fluorescence to define synaptic locations. Regions of interest (ROI) larger than 4 pixels were mapped onto the FM 4-64 signal and the average intensity (total integrated intensity/area) of spots determined. The average of these values in each image was calculated. The mean of wild-type images was used to normalize the data in that experiment. Five independent experiments were conducted.

Electrophysiological recording and analysis

Acquisition and analysis of whole cell voltage clamp recordings of synaptic responses in autaptic hippocampal neurons were performed as previously described (K. L. Custer et al., 2006), with the exception that recordings were performed under a controlled temperature between 21.0-22.5 °C.

Pull-down assays

All animal protocols used in these experiments were approved by the Institutional Animal Care and Use Committee of the University of Washington. 10-12 week old mice were sacrificed by cervical dislocation. Brains were removed immediately and homogenized in ice-cold homogenization buffer (0.32 M sucrose, 10mM HEPES, pH 7.4, 1×protease inhibitor cocktail (Roche)) and centrifuged at 1000 × g for 10 min at 4 °C. Triton X-100 was added to the resulting supernatants to a final concentration of 1%. The mixtures were extracted for 1 hour at 4 °C. Insoluble material was removed by centrifuging at 19,000 × g for 30 min. The protein concentration of the extract was determined by the BCA method using bovine serum albumin as a standard.

Recombinant SV2A-FLAG fusion proteins were expressed and purified as described previously (J. Yao and S. M. Bajjalieh, 2008). The concentration of purified fusion proteins was determined by running aliquots on SDS-PAGE gel followed by Coomassie Blue staining with bovine serum albumin as standards. SV2A-FLAG fusion proteins attached to anti-FLAG M2 affinity beads (3-6 ug SV2A fusion protein) were incubated with 1 mg brain extract for at least 3-16 hrs at 4 °C in the presence of 2mM EGTA. A parallel reaction was set up with protein-free beads. After incubation beads were washed with extraction buffer for 4 times, bound proteins were eluted with SDS-PAGE sample buffer or 3×FLAG peptide.

Proteomic analysis of SV2A binding proteins

SV2 amino terminus pull-down samples were eluted with 3×FLAG peptide, concentrated by trichloroacetic acid precipitation, and resuspended in SDS-PAGE sample buffer. Samples were electrophoresed briefly into the gel matrix after which gel slices were cut out and washed in 50% methanol, 7.5% acetic acid followed by 5% methanol, 7.5% acetic acid for 1 hr each. Gel slices were then washed three times in distilled water. Proteins in the gel slices were subjected to trypsin digestion, and the peptides were extracted and processed at the Proteomics Facility at Fred Hutchinson Cancer Research Center (Seattle, WA). Tryptic peptides were analyzed using a Thermo Finnigan LTQ-FT. A mouse proteome database was searched using X! Tandem software. PeptideProphet was used to assign scores for each peptide, and a ≥0.65 score was used which corresponded to a ~5% error rate. Three replicates of each pull-down assay were analyzed at the same time.

Surface biotinylation

Conventional cultures of hippocampal neurons were rinsed two times with cold phosphate-buffered-saline (PBS) (pH 8.0) and biotinylated by incubating with 0.5mg/ml EZ-LINK Sulfo-NHS-LC-LC-Biotin (Pierce) for 25 min at 4 °C. Cultures were washed with PBS (pH 7.4) and incubated with 100 mM glycine in PBS for 15 min to quench the reaction. After two rinses with PBS, neurons were harvested in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1mM EDTA, 1% NP-40, 1×protease inhibitor cocktail) and extracted for 30 min at 4 °C. Insoluble material was removed by centrifuging at 19,000 × g for 20 min. The supernatants were subjected to immunoprecipitation. Polyclonal anti-SV2A or anti-synaptotagmin 1 antibodies were conjugated to Protein A Sepharose beads (GE Healthcare) and incubated with the culture extract at 4 °C for ≥2 h. Beads were washed with RIPA buffer 4 times after which the immunoprecipitated complexes were eluted with SDS-PAGE sample buffer. Total immunoprecipitated protein was determined by Western blot using monoclonal antibodies against SV2 or synaptotagmin1. Antibody binding was detected with ECL reagent (Pierce). Biotinylated proteins were detected with Streptavidin-HRP and visualized with ECL reagent. The net intensity of labeled bands was quantified using a Kodak Image Station 440, and only nonsaturated images were used for quantification analysis.

Immunoisolation of synaptic vesicles

Synaptic vesicles from wild type and SV2A/B DKO mice were prepared by density centrifugation followed by immunoisolation. Brains were disrupted by blending in liquid nitrogen followed by homogenization in 0.3 M sucrose using a glass-teflon homogenizer. Homogenates were centrifuged at 100,000 × g for 1 hr and the resulting supernatants loaded onto a 0.6 M, 1.5 M sucrose step gradient. Gradients were centrifuged at 250,000 × g for 2.5 hrs. Synaptic vesicles were collected at the interface of the 0.6 and 1.5 M sucrose steps. Vesicles were exchanged into PBS by passing them through an equilibrated gel filtration P10 column (BioRad). Protein content was determined using the Bradford assay (BioRad) with BSA as a standard. For immunoisolation, polyclonal anti-synaptophysin antibody was bound to Protein A Sepharose, CL-4B beads and incubated overnight at 4 °C with 500ug of pre-cleared (with empty beads) synaptic vesicles. Beads were washed with PBS and processed for Western blot analysis.

Western analyses

The linear range was determined for each antibody used in Western analyses as previously reported (C. W. Morgans et al., 2009). An amount of mouse brain post-nuclear supernatant that fell within the linear range (e.g. 4 ug for anti-synaptotagmin) was assayed with actin serving as a loading control. In all cases the linear range for anti-vesicle protein antibodies fell within the linear range of anti-actin.

Statistical analysis

The data shown in Figures 2, ,3,3, ,5,5, ,6,6, ,77 and and99 are presented as means ± SEM. Statistical significance was determined using Student's t-test.

Figure 2
SV2A-EGFP but not SV2A-Y46A-EGFP restores normal neurotransmission to neurons from SV2A/B DKO mice
Figure 3
Reduced endocytosis of SV2A-Y46A
Figure 5
Reduced endocytosis of synaptotagmin 1 in neurons expressing SV2A-Y46A
Figure 6
Synaptic vesicles from SV2A/B DKO mice have less synaptotagmin
Figure 7
Expression of SV2 affects synaptotagmin expression
Figure 9
Mutation of the first endocytosis motif in SV2A results in a minimal change in synaptic endocytosis

Results

In an effort to understand SV2's molecular action, we mutated residues predicted to underlie proposed actions of SV2 and assessed their ability to rescue normal neurotransmission in neurons from SV2A/B double knockouts. SV2A contains two tyrosine-based endocytosis motifs, termed YXXΦ motifs, where Y denotes tyrosine, X denotes any amino acid (a.a.), and Φ denotes a hydrophobic a.a. The first endocytosis motif is at a.a. 46-49 with sequence YSRF, which is in SV2A's cytoplasmic amino terminus. The second motif is at the end of the cytoplasmic loop preceding transmembrane domain seven at a.a. 443-446 with sequence YRRI (Figure 1a). The first motif is shared by SV2C, and a variant sequence (YRMN) is present at the second site in SV2B. Peptides containing the YXXΦ motif from SV2A stimulate the binding of the clathrin adaptor AP2 to synaptotagmin (V. Haucke and P. De Camilli, 1999). Thus, these domains are predicted to facilitate vesicle protein endocytosis.

Figure 1
Expression of SV2A-EGFP fusion proteins in hippocampal neurons from SV2A/B DKO mice

To investigate the functional role of these putative endocytosis motifs in SV2, we generated SV2A-EGFP fusion proteins carrying a tyrosine-to-alanine mutation in one or both of the motifs. The resulting proteins, SV2A-Y46A, SV2A-Y443A, and SV2A-Y46A/Y443A, were expressed in hippocampal neurons cultured from SV2A/B DKO mice using a Lenti virus expression system. Wild-type and mutant fusion proteins were all produced by neurons. However, co-immunolabeling with anti-SV2A and an antibody against the synaptic vesicle protein synaptophysin revealed only wild-type SV2A and SV2A-Y46A were located at synapses (Figure 1b). Thus, mutation of Y443 disrupts trafficking of SV2A-EGFP. This mislocalized mutant was therefore not studied further. SV2A-Y46A, which did traffic to synapses, was expressed at comparable levels to wild-type SV2A as determined by Western blot analysis of conventional cultures (Figure 1c). The correct localization of the SV2A-Y46A mutant permitted analysis of its function in neurons.

Mutation of the first endocytosis motif in SV2A renders it non-functional and increases its surface expression

The hallmark features of neurons lacking SV2 are reduced action-potential-induced vesicle fusion and reduced synaptic depression (K. L. Custer et al., 2006; W. P. Chang and T. C. Sudhof, 2009). Both of these reflect reduced synaptic release probability. To evaluate the role of the endocytosis motif in SV2A function at the synapse, we compared the ability of wild-type SV2A and SV2A-Y46A to rescue EPSC amplitude and synaptic depression in autaptic hippocampal neurons from SV2A/B DKO mice. We assessed the effects of expressing EGFP, SV2A-EGFP, and SV2A-Y46A-EGFP on EPSC amplitude and total charge transfer, increased paired pulse ratio (the ratio of a second response in relation to the first in a pair of stimuli), and decreased synaptic depression (K. L. Custer et al., 2006; W. P. Chang and T. C. Sudhof, 2009). Lentiviral-mediated expression of SV2A-EGFP significantly increased the average EPSC amplitude and total charge transfer in comparison to DKO neurons expressing EGFP (Figure 2a, b). Likewise, normal paired pulse ratios and synaptic depression were restored in neurons expressing SV2A-EGFP (Figure 2c, d). Similar results have been reported for cultures of cortical neurons expressing EGFP-SV2A (W. P. Chang and T. C. Sudhof, 2009). Thus, the addition of EGFP to SV2A does not impair its function at the synapse. This finding also indicates that the neurotransmission deficit in neurons from SV2A/B DKO mice is due to the absence of SV2.

In contrast to wild-type SV2A-EGFP, expression of SV2A-Y46A-EGFP did not significantly increase EPSC amplitude or total charge transfer (Figure 2a, b). Nor did it restore synaptic depression. Both paired pulse ratios and responses to 10 Hz and 20 Hz stimulus trains demonstrated facilitation, unlike the depression observed in neurons expressing wild-type SV2A (Figure 2c, d). Because EPSC size and synaptic depression are indicative of synaptic release probability (L. E. Dobrunz and C. F. Stevens, 1997), these findings indicate that SV2A-Y46A, unlike wild-type SV2A, did not restore normal neurotransmission at synapses. This suggests tyrosine 46 is essential to normal SV2 function.

To determine whether mutation of this endocytosis motif affects the endocytosis of SV2, we compared the proportion of SV2 on the plasma membrane by labeling surface proteins with biotin. For these studies, we used conventional cultures of hippocampal neurons from SV2A/B DKO mice because they contain many more neurons and fewer astrocytes than autaptic cultures. Cultures were infected with Lenti virions encoding EGFP, SV2A-EGFP, or SV2A-Y46A-EGFP on DIV 1-3. At DIV 13-15, 90-95% of neurons were expressing the proteins. Surface proteins were labeled using a membrane-impermeant reactive biotin reagent after which cultures were harvested, extracted in NP-40, and subjected to immunoprecipitation using an antibody directed against SV2A. The precipitated protein was subjected to two Western analyses, one to probe for the total amount of SV2A precipitated and one for SV2A biotinylation to measure the amount that was on the neuronal surface. The intensity of the biotinylation signal was expressed as a ratio of the total SV2 signal. Values were normalized within each experiment to the ratio obtained from cultures expressing wild-type SV2A. Compared this way, we found neurons expressing SV2A-Y46A had an average of ~45% more biotinylated SV2A (Figure 3). Thus, the endocytosis motif at the amino terminus of SV2A plays a role in its internalization.

The endocytosis motif in SV2A mediates binding to proteins involved in endocytosis

To begin to understand how the tyrosine-based motif of SV2A contributes to endocytosis we performed a proteomic screen to identify protein interactions dependent on an intact endocytosis motif. We used recombinant proteins corresponding to amino acids 1-163 of SV2A or SV2A-Y46A as bait to screen mouse brain extract for proteins that preferentially bound wild-type SV2A. Associated proteins were subjected to trypsin digestion followed by reverse-phase liquid chromatography tandem mass spectrometry (LC–MS/MS). Data analysis and statistical scoring of peptide identifications were done with Peptide Prophet, a program developed by Aebersold and colleagues (A. Keller et al., 2002). Table 1 lists proteins that were identified in three replicates as having at least two-fold more peptide fragments associated with wild-type SV2A1-163. Included were multiple clathrin adaptor proteins (reviewed in (L. Maldonado-Baez and B. Wendland, 2006)), including all four subunits of AP2, subunits of AP1 and AP3, two isoforms of EPS15 and numb-like protein. In addition to adaptors, other endocytosis-related proteins were identified including endophilin interacting protein 1, intersectin 1, AP2-associated protein kinase 1, and two isoforms of amphiphysin.

Table 1
A screen for proteins that bind preferentially to the amino terminus of wild-type SV2A

In addition to the proteins included in Table 1, which was restricted to proteins for which more than 10 peptides were identified, there were several proteins with <10 peptides identified that demonstrated preferential binding to wild-type SV2A. These included synaptotagmin 1 (4 peptides identified in wild-type samples versus one with the mutant) and Numb protein (6 peptides vs. 0). This may reflect a bias in the procedure (e.g. fewer tryptic cleavage sites or poor extraction from gel matrix). On the other hand, it is also consistent with the endocytosis motif of SV2 having the highest affinity for endocytosis-related proteins. Note that the absence of proteins acting later in endocytosis (e.g. dynamin, synaptojanin) suggests that the amino terminus of SV2A mediates interactions relevant to early endocytotic events. The high level of apparent binding to AP2 is consistent with SV2 acting at the point of cargo recognition.

To verify the results of the proteomic screen, we performed Western analyses on proteins isolated with SV2A's amino terminus and also with full-length SV2A. Both the amino terminus and full-length wild-type SV2A bound the clathrin adaptor proteins AP2-alpha and EPS15. Full-length SV2A showed weak but detectable binding to Amphiphysin 2 (Bin1). In both cases, binding was higher in wild-type SV2A than in SV2A-Y46A (Figure 4).

Figure 4
The Y46A mutation disrupts SV2A binding to endocytosis-related proteins

SV2 influences synaptotagmin 1 trafficking and expression

SV2 is part of a large protein complex that includes the synaptic vesicle protein synaptotagmin 1 (M. K. Bennett et al., 1992; A. E. Schivell et al., 1996; A. E. Schivell et al., 2005). SV2 is hypothesized to influence the endocytosis of synaptotagmin because peptides corresponding to the endocytosis domain in SV2A increase binding of synaptotagmin to the adaptor protein, AP2 (V. Haucke and P. De Camilli, 1999). It was possible that the Y46A mutation might affect the endocytosis of synaptotagmin. To test this, we assessed the effects of the Y46A mutation on surface levels of the synaptic vesicle protein synaptotagmin 1. We found that expression of SV2A-Y46A resulted in a ~50% increase in the proportion of biotinylated synaptotagmin 1 compared to neurons expressing wild-type SV2A (Figure 5). An even greater (2-fold) increase in biotinylated synaptotagmin 1 was observed in DKO cultures expressing EGFP (which lack SV2A/B). A less extensive analysis of the vesicle protein synaptophysin revealed no change in surface expression in neurons expressing SV2A-Y46A (not shown). This suggests that the effect is specific to synaptotagmin and is consistent with synaptophysin's absence from the SV2 protein complex (A. E. Schivell et al., 1996).

If SV2 is required for proper trafficking of synaptotagmin to synaptic vesicles, we would expect vesicles isolated from mice lacking SV2 to contain less synaptotagmin. We therefore compared the amount of synaptotagmin in vesicles immunoisolated from either wild-type or SV2A/B DKO mouse brain. Vesicles were purified using an antibody to synaptophysin and the amount of synaptotagmin in them determined. The ratio of synaptotagmin to synaptophysin was 85% lower in vesicles from SV2A/B DKO mice (Figure 6). In contrast, there was no decrease in the levels of VAMP2/synaptobrevin or the vesicular glutamate transporter 1 (VGlut1). There was a small (25%) decrease in synaptogyrin, which may result from decreased expression (see below). Thus, SV2 appears to play a specific role in trafficking a subset of proteins to synaptic vesicles, with the largest effect on synaptotagmin. Coupled with our observation that SV2 influences the internalization of synaptotagmin, these results support the conclusion that SV2 plays a major role in regulating the amount of synaptotagmin in synaptic vesicles.

Immunoblot analyses of protein expression revealed that synaptotagmin levels were ~50% lower in neurons lacking SV2. Expression of either wild-type SV2A or SV2A-Y46A restored total synaptotagmin expression (Figure 7a). This decrease reflects diminished synaptic levels of synaptotagmin as determined by immunolabeling studies, which revealed a near identical (52%) decrease in synapses lacking SV2A/B compared to synapses expressing either wild-type SV2A-EGFP or SV2A-Y46A-EGFP (Figure 7b). The fact that both wild-type and mutant SV2A restored normal levels of synaptotagmin indicates that SV2A influences synaptotagmin expression via a mechanism that is independent of its affects on synaptotagmin trafficking, perhaps by inhibiting protein turnover.

The decreased synaptotagmin in neurons cultured from SV2A/B knockout mice stands in contrast to previously published results that reported no change in brain levels of synaptotagmin in similar mice (R. Janz et al., 1999). We therefore repeated analyses of protein expression in wild-type and SV2A/B knockout mice, taking care to make sure the amount of protein assayed was in the linear range of the Western analysis. When performed in this way, we observed a selective decrease in synaptotagmin (~50%) (Figure 7c, d), and synaptogyrin (~40%) (Figure 7d) in brain post nuclear supernatants from SV2A/B knockout mice. Levels of other major vesicle proteins were not significantly altered. Nor was there a difference in whole brain levels (Figure 7d) or synaptic levels (not shown) of the clathrin adaptor proteins AP2 and Amphiphysin 2/Bin1. Thus SV2 exerts a selective effect on vesicle protein expression and is required for normal levels of synaptotagmin in vivo as well as in culture. The decreased expression of synaptogyrin matches the decrease in vesicle content, suggesting that vesicle content tracks expression levels for this protein. In contrast, the decrease in total synaptotagmin expression (~50%) is not as great as the decrease in synaptic vesicle content (85%), consistent with SV2 influencing both the expression and trafficking of synaptotagmin.

The tyrosine-based endocytosis motif in SV2 is required for binding to clathrin adaptor proteins

SV2 contains two synaptotagmin-binding sites: one, unique to SV2A and SV2C, that overlaps with the tyrosine-based endocytosis motif in the cytoplasmic amino terminus, and a second, more diffuse, site that is present in all three SV2 isoforms (A. E. Schivell et al., 2005). To determine if the Y46A mutation influences binding to synaptotagmin, we compared the ability of wild-type SV2A and SV2A-Y46A to bind synaptotagmin in vitro. Interestingly, we found that the Y46 mutation reduced synaptotagmin binding to the isolated amino terminus but not to full-length SV2A (Figure 8). Therefore it appears that SV2A's first endocytosis motif contributes to synaptotagmin binding, but that the second site (present in all isoforms) can support normal levels of synaptotagmin binding. Because full-length SV2A-Y46A demonstrated decrease binding to clathrin adaptors (Figure 4), but not to synaptotagmin, it appears that SV2's interaction with clathrin adaptors does not occur through synaptotagmin. These findings support the interpretation that the amino terminal endocytosis motif of SV2A is a receptor for clathrin adaptor proteins.

Figure 8
The Y46A mutation affects synaptotagmin binding to the amino terminus of SV2A but not to full length SV2A

Loss of SV2 has a minor effect on synaptic endocytosis

Given the effect of the Y46A mutation on clathrin adaptors, we sought to determine if disrupted endocytosis of SV2 affects the retrieval of synaptic vesicles during synaptic activity. We assessed membrane internalization by measuring the uptake of the fixable FM dye, FM 4-64FX in response to prolonged depolarization, and observed that synapses expressing SV2A-Y46A took up, on average, 15% less FM 4-64FX dye than synapses expressing wild-type SV2A (Figure 9). Because our analysis was limited to synaptic puncta that contained SV2A-EGFP, we did not quantify synaptic endocytosis in neurons from SV2A/B knockout (DKO) mice expressing EGFP; however, qualitative analysis of the images indicated that a similar decrease was seen in neurons lacking SV2. This small difference could result from the decreased exocytosis that occurs in synapses lacking wild-type SV2 or it could indicate that SV2 provides a modest contribution to vesicle endocytosis. The magnitude of the effect, however, was too small to account for the changes in neurotransmission or vesicle content of synaptotagmin seen in neurons lacking SV2.

Discussion

Based on its structure, SV2 has been proposed to perform several actions, including transport of ions or small molecules into vesicles (R. Janz et al., 1999), providing the glyco-matrix to the vesicle lumen (D. Reigada et al., 2003), and modulating the endocytosis of vesicle proteins (V. Haucke and P. De Camilli, 1999). The findings presented here demonstrate that SV2 serves as a receptor for clathrin adaptor proteins and contributes to the proper trafficking of the vesicle protein synaptotagmin.

Mutation of Y46, which is part of a canonical YXXΦ adaptor-binding site (D. J. Owen and P. R. Evans, 1998) in the amino terminus of SV2A-EGFP, produced a protein that trafficked to synapses but did not support normal neurotransmission. In comparison to wild-type SV2A, SV2A-Y46A demonstrated reduced binding to multiple endocytosis-related proteins, including AP2, EPS15, and Amphiphysin 2 (Bin1). Consistent with reduced binding to the mediators of endocytosis, the Y46A mutation resulted in lowered internalization of SV2. Because SV2A contains two YXXΦ motifs, our results suggest that the amino terminal endocytosis motif in SV2A plays a dominant role in its endocytosis.

The findings presented here appear to conflict with the observation that an EGFP-SV2A fusion protein lacking a.a. 1-107 of SV2A is functional (W. P. Chang and T. C. Sudhof, 2009). While this could indicate that the Y46A mutation produces a dominant negative effect, we note that EGFP protein contains a sequence that could serve as a tyrosine-based endocytosis motif (YGKL) at a.a. 40-43. Given the nearly identical position of this motif to that in the amino terminus of native SV2A (a.a. 46-49), it is possible that the EGFP-SV2A fusion protein expressed in those studies was capable of binding clathrin adaptors.

Disruption of the endocytosis motif in SV2A's amino terminus resulted in a higher proportion of synaptotagmin on the plasma membrane. This finding is consistent with SV2 playing an important role in the endocytosis of synaptotagmin. While we cannot rule out the possibility that increased surface synaptotagmin was due to increased delivery to the plasma membrane, when viewed in light of our finding that synaptic vesicles from SV2A/B knockout mice contained significantly lower amounts of synaptotagmin, the most compatible conclusion is that SV2 regulates the endocytosis of synaptotagmin. Synaptotagmin has been proposed to be required for normal vesicle endocytosis (E. M. Jorgensen et al., 1995; K. E. Poskanzer et al., 2003; K. Nicholson-Tomishima and T. A. Ryan, 2004) and to be a clathrin adaptor receptor (J. Z. Zhang et al., 1994; E. R. Chapman et al., 1998; M. K. Diril et al., 2006). Our findings suggest that SV2 contributes to any role synaptotagmin plays in endocytosis. We note with interest that our proteomic screen for proteins that bind the amino terminus of SV2A did not identify stonin 2, a homolog of the mu subunit of AP2 (J. A. Martina et al., 2001) that mediates the endocytosis of synaptotagmin (M. K. Diril et al., 2006). SV2's ability to affect synaptotagmin endocytosis may therefore be through regulating synaptotagmin's ability to bind stonin 2. Alternatively, by simultaneously engaging mu through its YXXΦ motif and interacting with synaptotagmin bound to stonin 2, SV2 may help concentrate clathrin adaptors in a way that insures the inclusion of synaptotagmin in vesicles.

In addition to influencing the trafficking of synaptotagmin, SV2 also exerts a selective effect on the expression of synaptotagmin. Synaptotagmin levels were considerably lower in both brain homogenates and neuron cultures from SV2A/B knockout mice. A similar finding was reported in the retina of mice lacking SV2B (D. R. Lazzell et al., 2004; C. W. Morgans et al., 2009), which is the predominant SV2 isoform in photoreceptor synapses. This indicates that the ability to stabilize synaptotagmin is not mediated by the amino terminus of SV2, since the A and B isoform of SV2 have significantly different amino termini. Consistent with this interpretation, both wild-type SV2A and SV2A-Y46A restored higher levels of synaptotagmin expression. The fact that expression of SV2A-Y46A rescued synaptotagmin expression but not its endocytosis suggests that the way in which SV2 affects synaptotagmin levels differs from the way it impacts synaptotagmin endocytosis.

Although the expression of SV2A-Y46A resulted in a modest decrease in endocytosis, the small magnitude of the effect, combined with normal vesicle number and morphology in SV2 knockouts (K. M. Crowder et al., 1999; R. Janz et al., 1999), suggests that SV2 does not play a major role in vesicle biosynthesis. The smallness of the effect also suggests that reduced endocytosis is not likely to account for the significant decrease in neurotransmission observed in neurons expressing SV2A-Y46A. Finally, the disparity between the magnitude of SV2A-Y46A's effects on endocytosis and synaptotagmin internalization suggests that SV2 has a specific effect on synaptotagmin trafficking.

SV2 is essential for normal neurotransmission. In its absence, synaptic release probability decreases, a result that leads to a severe seizure phenotype and premature death (K. M. Crowder et al., 1999; R. Janz et al., 1999). The functional lesion in synapses lacking SV2 occurs after vesicle docking (K. L. Custer et al., 2006) and before the formation of tightly-associated SNARE complexes (T. Xu and S. M. Bajjalieh, 2001), indicating SV2 contributes to the process that renders vesicles competent for calcium-stimulated fusion. Altered endocytosis could produce this phenotype by changing the protein composition of vesicles. Based on the findings presented here, a model emerges in which SV2A, via interaction with both synaptotagmin and clathrin adaptors, regulates the vesicle content of synaptotagmin. In the absence of SV2, synaptotagmin trafficking to synaptic vesicles becomes more random, leading to fewer vesicles with enough of the calcium sensor to trigger calcium-stimulated fusion. Thus this action of SV2 can explain the neurotransmission deficit observed in SV2 knockouts.

Clues to SV2's molecular action have come largely from its structure. SV2's most striking feature is its structural similarity to MF transporters (S. S. Pao et al., 1998), which has led to the widely held hypothesis that it transports something across the vesicle membrane. Although most proteins with transporter-like structure are transporters, there are several that perform other functions. A particularly interesting example is unc93b, a recently characterized transporter-like protein that plays a crucial role in trafficking Toll-like receptors to endosomes (M. M. Brinkmann et al., 2007; Y. M. Kim et al., 2008). Our findings provide another example of a transporter-like protein acting as a modulator of protein trafficking to endosomes. While we don't know if the Y46A mutation also affects a transport activity of SV2, the finding that it renders SV2A non-functional and affects the endocytosis of synaptotagmin supports the conclusion that modulation of endocytosis is an essential action of SV2.

Acknowledgments

This work was supported by a grant from the National Institute of Mental Health (R01 MH 059842) to SB. We thank Drs. Beverly Wendland and John Scott for comments on the manuscript, Greg Martin of the U. W. Keck Imaging Center for help with imaging, and Lisa Baldwin for animal husbandry and editorial comments on the manuscript.

The abbreviations used are

SV2
synaptic vesicle protein 2
a.a
amino acid
DKO
double-knockout

References

  • Bajjalieh SM, Franz G, Weimann JM, McConnell SK, Scheller RH. Differential expression of Synaptic Vesicle Protein 2 (SV2) isoforms. The Journal of Neuroscience. 1994;14:5223–5235. [PubMed]
  • Bennett MK, Calakos N, Kreiner T, Scheller RH. Synaptic vesicle membrane proteins interact to form a multimeric complex. J Cell Biol. 1992;116:761–775. [PMC free article] [PubMed]
  • Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol. 2007;177:265–275. [PMC free article] [PubMed]
  • Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology. 2005;64:1078–1080. [PubMed]
  • Chang WP, Sudhof TC. SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis. J Neurosci. 2009;29:883–897. [PMC free article] [PubMed]
  • Chapman ER, Desai RC, Davis AF, Tornehl CK. Delineation of the oligomerization, AP-2 binding, and synprint binding region of the C2B domain of synaptotagmin. J Biol Chem. 1998;273:32966–32972. [PubMed]
  • Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) Proceedings of the National Academy of Science, USA. 1999;96:115268–115273. [PMC free article] [PubMed]
  • Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci. 2006;26:1303–1313. [PubMed]
  • De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007;13:57–78. [PubMed]
  • Diril MK, Wienisch M, Jung N, Klingauf J, Haucke V. Stonin 2 is an AP-2-dependent endocytic sorting adaptor for synaptotagmin internalization and recycling. Dev Cell. 2006;10:233–244. [PubMed]
  • Dobrunz LE, Stevens CF. Heterogeneity of release probability, facilitation, and depletion at central synapses. Neuron. 1997;18:995–1008. [PubMed]
  • Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother. 2005;19:35–43. [PubMed]
  • Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain. 2006;10:193–198. [PubMed]
  • Haucke V, De Camilli P. AP-2 recruitment to synaptotamin stimulated by tyrosine-based endocytic motifs. Science. 1999;285:1268–1271. [PubMed]
  • Janz R, Goda Y, Geppert M, Missler M, Sudhof TC. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron. 1999;24:1003–1016. [PubMed]
  • Jorgensen EM, Hartwieg E, Schuske K, Nonet ML, Jin Y, Jorvitz HR. Defective recycling of synaptic vesicles in synaptotagmin mutants of Caenorhabditis elegans. Nature. 1995;378:196–199. [PubMed]
  • Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002;74:5383–5392. [PubMed]
  • Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature. 2008;452:234–238. [PubMed]
  • Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006;67:211–214. [PubMed]
  • Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007;68:1010–1013. [PubMed]
  • Lazzell DR, Belizaire R, Thakur P, Sherry DM, Janz R. SV2B regulates synaptotagmin 1 by direct interaction. J Biol Chem. 2004;279:52124–52131. [PubMed]
  • Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101:9861–9866. [PMC free article] [PubMed]
  • Maldonado-Baez L, Wendland B. Endocytic adaptors: recruiters, coordinators and regulators. Trends Cell Biol. 2006;16:505–513. [PubMed]
  • Martina JA, Bonangelino CJ, Aguilar RC, Bonifacino JS. Stonin 2: an adaptor-like protein that interacts with components of the endocytic machinery. J Cell Biol. 2001;153:1111–1120. [PMC free article] [PubMed]
  • McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology. 2003;61:419. [PubMed]
  • Morgans CW, Kensel-Hammes P, Hurley JB, Burton K, Idzerda R, McKnight GS, Bajjalieh SM. Loss of the Synaptic Vesicle Protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. PLoS ONE. 2009;4:e5230. [PMC free article] [PubMed]
  • Nicholson-Tomishima K, Ryan TA. Kinetic efficiency of endocytosis at mammalian CNS synapses requires synaptotagmin I. Proc Natl Acad Sci U S A. 2004;101:16648–16652. [PMC free article] [PubMed]
  • Owen DJ, Evans PR. A structural explanation for the recognition of tyrosine-based endocytotic signals. Science. 1998;282:1327–1332. [PubMed]
  • Pao SS, Paulsen IT, Saier MH., Jr Major facilitator superfamily. Microbiol Mol Biol Rev. 1998;62:1–34. [PMC free article] [PubMed]
  • Poskanzer KE, Marek KW, Sweeney ST, Davis GW. Synaptotagmin I is necessary for compensatory synaptic vesicle endocytosis in vivo. Nature. 2003;426:559–563. [PubMed]
  • Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain. 2004;20:33–36. [PubMed]
  • Reigada D, Diez-Perez I, Gorostiza P, Verdaguer A, Gomez de Aranda I, Pineda O, Vilarrasa J, Marsal J, Blasi J, Aleu J, Solsona C. Control of neurotransmitter release by an internal gel matrix in synaptic vesicles. Proc Natl Acad Sci U S A. 2003;100:3485–3490. [PMC free article] [PubMed]
  • Schivell AE, Batchelor RH, Bajjalieh SM. Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem. 1996;271:27770–27775. [PubMed]
  • Schivell AE, Mochida S, Kensel-Hammes P, Custer KL, Bajjalieh SM. SV2A and SV2C contain a unique synaptotagmin-binding site. Mol Cell Neurosci. 2005;29:56–64. [PubMed]
  • Striano P, Elefante A, Coppola A, Tortora F, Zara F, Minetti C, Striano S. Dramatic response to levetiracetam in post-ischaemic Holmes' tremor. J Neurol Neurosurg Psychiatry. 2007;78:438–439. [PMC free article] [PubMed]
  • Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546–554. [PubMed]
  • Xu T, Bajjalieh SM. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nature Cell Bio. 2001;3:691–698. [PubMed]
  • Yao J, Bajjalieh SM. Synaptic vesicle protein 2 binds adenine nucleotides. J Biol Chem. 2008;283:20628–20634. [PMC free article] [PubMed]
  • Zhang JZ, Davletov BA, Sudhof TC, Anderson RGW. Synaptotagmin I is a high affinity receptor for clathrin AP-2: Implications for membrane recycling. Cell. 1994;78:751–760. [PubMed]
  • Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005;19:551–553. [PubMed]
  • Zivkovic SA, Costa G, Bond G, Abu-Elmagd KM. Treatment of tardive dyskinesia with levetiracetam in a transplant patient. Acta Neurol Scand. 2008;117:351–353. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...